8.-10. November 2024
Houston, USA
- Pressemitteilung
- Konferenzwebsite
- Preliminary immunogenicity results from the dose escalation phase of a first-in-human study of the mRNA-based cancer vaccine CVGBM in patients with newly diagnosed MGMT-unmethylated glioblastoma
- mRNA vaccination enhances TCRtg T cell therapy efficacy in solid tumors
- Identification and validation of a T cell receptor recognizing shared HLA-A02:01 presented epitope from TP53 frameshift